Merrion to Develop Insulin Drugs with Novo

By Taskin Ahmed

Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)

Published: 24 Nov-2008

DOI: 10.3833/pdr.v2008.i102.106     ISSN: 1756-7874

Section: Licensing



Novo Nordisk signed an agreement to develop oral insulin analogues using Merrion Pharmaceuticals’ Gastrointestinal Permeation Enhancement Technology (GIPET) in a deal valued at €45 M (US$58 M)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details